Fig. 5: Clemastine has subtler and more protracted actions on remyelination.

A Treatment groups. B Cumulative OL loss and gain (as a percentage of baseline OLs) in individual mice over time (vehicle: n = 4, clemastine: n = 7). C Cumulative OL loss at 3 weeks does not differ between groups in mean or variance. D Clemastine increases OL gain rate (as a percentage of baseline OLs/day) from 3 to 5 weeks. E Clemastine does not change maximum OL gain rate (as a percentage of baseline OLs/day) during remyelination. F Clemastine does not significantly increase cumulative OL gain. G OL number (as a percentage of baseline OLs) is correlated with cumulative OL loss at 7 weeks in mice treated with clemastine. In (C), t test (t(9) = −1.37, p = 0.20). Brown-Forsythe (F(1,9) = 0.043, p = 0.84). Vehicle: n = 4, clemastine: n = 7. In (D) 0-1.5w, ANCOVA with unequal slopes in Supplementary Fig. 11A not significant. Vehicle: n = 4, clemastine: n = 7. In (D) 1.5-3w, no effect of treatment in ANCOVA with unequal slopes in Supplementary Fig. 11B. Vehicle: n = 4, clemastine: n = 7. In (D) 3-5w, post-hoc t test (t(5) = 6.73, **p = 0.0011). Vehicle: n = 4, clemastine: n = 5. In (E), ANCOVA with unequal slopes in Supplementary Fig. 11F not significant. Vehicle: n = 4, clemastine: n = 7. In (F), ANCOVA with unequal slopes in Supplementary Fig. 11G-I not significant. 1.5 and 3w: vehicle: n = 4, clemastine: n = 7. 7w: vehicle: n = 3, clemastine: n = 7. In (G), linear regression (F(1, 2) = 25.75, n = 4). **p < 0.01; mean ± SEM in (C); least square mean ± SEM in (D–F); line of best fit in (G); n=mice; two-sided statistical tests. See Supplementary Data 1 for statistical details and Source Data file for source data. OL=oligodendrocyte.